Stratos Wealth Advisors’s GSK GSK Stock Holding History

Stratos Wealth Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,675	Closed	-$232K	–	740
2024 Q3	$232K	Buy	5,675 +2	+0%	+$82	0.01%	674
2024 Q2	$218K	Buy	5,673 +83	+1%	+$3.49K	0.01%	645
2024 Q1	$240K	Sell	5,590 -1,432	-20%	-$59.1K	0.01%	591
2023 Q4	$260K	Sell	7,022 -368	-5%	-$13.2K	0.02%	582
2023 Q3	$268K	Buy	+7,390	New	+$262K	0.02%	557
2022 Q3	–	Sell	-6,711	Closed	-$365K	–	507
2022 Q2	$365K	Buy	6,711 +182	+3%	+$10K	0.03%	411
2022 Q1	$356K	Buy	6,529 +849	+15%	+$46.1K	0.03%	426
2021 Q4	$313K	Buy	5,680 +408	+8%	+$21.2K	0.02%	456
2021 Q3	$252K	Buy	5,272 +607	+13%	+$30.5K	0.02%	452
2021 Q2	$232K	Buy	4,665 +3	+0.1%	+$144	0.02%	487
2021 Q1	$208K	Buy	+4,662	New	+$212K	0.02%	460
2020 Q3	–	Sell	-4,149	Closed	-$212K	–	311
2020 Q2	$212K	Buy	+4,149	New	+$213K	0.07%	250

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Stratos Wealth Advisors's GSK Position: Q4 2024 in Review

Stratos Wealth Advisors sold out of GSK (GSK) in Q4 2024, closing a stake of 5,675 shares — an estimated $232K sold.

Stratos Wealth Advisors first reported a position in GSK in Q2 2020 and held it in 12 quarters. The position peaked at $365K in Q2 2022. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

Stratos Wealth Advisors reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
Stratos Wealth Advisors sold 5,675 GSK shares in Q4 2024, an estimated $232K.
Stratos Wealth Advisors first reported a position in GSK in Q2 2020 and held it in 12 quarters.
Stratos Wealth Advisors's GSK position peaked at $365K in Q2 2022.
848 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on Stratos Wealth Advisors's 13F filing for Q4 2024, filed 27 Jan 2025.